Bayer Intellectual Property Gmbh

Bayer Pharma Aktiengesellschaft

Bayer Animal Health Gmbh

Adverio Pharma Gmbh

Bayer Schering Pharma Ag

Elanco Animal Health Gmbh

Bayal Animal Health Gmbh

Nils Griebenow

Frank Wunder

Johannes-Peter Stasch

Gorden Redlich

Markus Follmann

Andreas Knorr

Volkhart Min-Jian Li

Jens Ackerstaff

Karl-Heinz Schlemmer

Hans-Georg Schwarz

Joachim Mittendorf

Walter Hübsch

Eva-Maria Becker

Johannes Köbberling

Wei Zhuang

Rolf Jautelat

Daniel Kulke

Walter Kroh

Hans-Georg Lerchen

Donald Bierer

Elke Hartmann

Thomas Simon Ilg

Dieter Lang

Adeline Köhler

Ulrich Görgens

Sven Wittrock

Iring Heisler

Claudia Böhm

Rudolf Schohe-Loop

Bernd Alig

Niels Lindner

Ingo Flamme

Claudia Welz

Kirsten Börngen

Adrian Tersteegen

Alexandros Vakalopoulos

Stefan Heitmeier

Beatrix Stelte-Ludwig

Yolanda Cancho Grande

Simone Greven

Christoph Mahlert

Maike Hink

Anette Sommer

Maria Köllnberger

Julie Marley

Iain Pritchard

Peter Kolkhof

Michael Hahn

Thomas Lampe

Lars Bärfacker

Axel Kretschmer

Anne-Sophie Rebstock

Friederike Stoll

Hartmut Beck

Jan Tebbe

Frank Süβmeier

Sherif El Sheikh

Oliver Kensch

Walter Huebsch

Hilmar Bischoff

Alexander Straub

Pierre Wasnaire

Ulf Bömer

Werner Hallenbach

Carsten Schmeck

Klemens Lustig

Wahed Ahmed Moradi

Anja Buchmüller

Siegfried Zaiss

Elisabeth Pook

Claudia Hirth-Dietrich

Hartmut Schirok

Chantal Fürstner

Marcus Bauser

Stefan Weigand

Mario Lobell

Michael Härter

Ursula Krenz

Ulrich Ebbinghaus-Kintscher

Klaus Münter

Leila Telan

Holger Paulsen

Niels Svenstrup

Ulf Brüggemeier

Martin Adamczewski

Timo Flessner

Barbara Albrecht

Dirk Schneider

Thomas Mondritzki

Sandra Berndt

Carsten Terjung

Mark Meininghaus

Klaus Raming

Michael Gerisch

Adeline Koehler

Elisabeth Woltering

Frank Süssmeier

Peter Ellinghaus

Kirsten Boerngen

Florian Kölling

The present invention relates to novel compounds of general formula (I): withA being A1 or A: andin which T, X, Y, Ro, R, Rand Rare as defined herein, methods of preparing said compounds, intermediate compounds useful for preparing said compounds, pharmaceutical compositions and combinations comprising said compounds and the use of said compounds for the treatment, control and/or prevention of diseases, in particular of helminth infections, as a sole agent or in combination with other active ingredients.

Anthelmintic compounds

The present invention covers new isoquinoline compounds of general formula (I): in which A, R, R, R, R, R, R, and Q are as defined herein, methods of preparing the compounds, intermediate compounds useful for preparing the compounds of formula (I), pharmaceutical compositions and combinations comprising the compounds of formula (I) and the use of the compounds of formula (D) for manufacturing pharmaceutical compositions for the treatment, control and/or prevention of diseases, in particular of helminth infections, as a sole agent or in combination with other active ingredients.

Isoquinoline derivatives and their use for the treatment of parasitic infections

The present application relates to novel substituted 5-fluoro-1H-pyrazolopyridines, to processes for their preparation, to their use alone or in combinations for the treatment and/or prophylaxis of diseases, and to their use for producing medicaments for the treatment and/or prophylaxis of diseases, in particular for the treatment and/or prophylaxis of cardiovascular disorders.

Substituted 5-fluoro-1H-pyrazolopyridines and their use

The invention relates to site specific homogeneous binder drug conjugates of kinesin spindle protein inhibitors, to active metabolites of these conjugates, to processes for preparing these conjugates, to the use of these conjugates for the treatment and/or prophylaxis of diseases and to the use of these conjugates for preparing medicaments for treatment and/or prevention of diseases, in particular hyperproliferative and/or angiogenic disorders such as, for example, cancer diseases. Such treatments can be carried out as monotherapy or else in combination with other medicaments or further therapeutic measures.

Site specific homogeneous with KSP inhibitors

The present invention covers new quinoline compounds of general formula (I), in which A, R, R, R, R, R, R, and Q are as defined herein, methods of preparing said compounds, intermediate compounds useful for preparing said compounds, pharmaceutical compositions and combinations comprising said compounds and the use of said compounds for manufacturing pharmaceutical compositions for the treatment, control and/or prevention of diseases, in particular of helminth infections, as a sole agent or in combination with other active ingredients. 

Quinoline derivatives

The present invention covers azaquinoline compounds of general formula (I), with A being (A1) or (A2), and in which T, R, R, R, R, R, Rand Q are as defined herein, methods of preparing said compounds, intermediate compounds useful for preparing said compounds, pharmaceutical compositions and combinations comprising said compounds and the use of said compounds for manufacturing pharmaceutical compositions for the treatment, control and/or prevention of diseases, in particular of helminth infections, as a sole agent or in combination with other active ingredients. 

Azaquinoline derivatives

The present invention covers quinoline compounds of general formula (I), in which A, R, R, R, R, R, R, and Q are as defined herein, methods of preparing said compounds, intermediate compounds useful for preparing said compounds, pharmaceutical compositions and combinations comprising said compounds and the use of said compounds for manufacturing pharmaceutical compositions for the treatment, control and/or prevention of diseases, in particular of helminth infections, as a sole agent or in combination with other active ingredients. 

Quinoline derivatives for treating infections with helminths

The present invention covers bicyclic pyrazole compounds of general formula (I): in which G, A, R, R, R, and Q are as defined herein, methods of preparing said compounds, intermediate compounds useful for preparing said compounds, pharmaceutical compositions and combinations comprising said compounds and the use of said compounds for manufacturing pharmaceutical compositions for the treatment, control and/or prevention of diseases, in particular of helminth infections, as a sole agent or in combination with other active ingredients. 

Bicyclic pyrazole derivatives

The present application relates to the use of fused heteroaromatic pyrrolidones for treatment and/or prophylaxis of allergic and/or inflammatory diseases in animals and to the use thereof for production of medicaments for treatment and/or prophylaxis of allergic and/or inflammatory diseases in animals, especially of atopic dermatitis and/or Flea Allergy Dermatitis, and especially in domestic animals, particularly in dogs.

Use of fused heteroaromatic pyrrolidones for treatment and prevention of diseases in animals

The present invention covers Pyrazolopyrimidine compounds of general formula (I): in which n, o, X, Y, R, Q, R, R, Rand Rare as defined herein, methods of preparing said compounds, intermediate compounds useful for preparing said compounds, pharmaceutical compositions and combinations comprising said compounds and the use of said compounds for manufacturing pharmaceutical compositions for the treatment, control and/or prevention of diseases, in particular of helminth infections, as a sole agent or in combination with other active ingredients.

Pyrazolopyrimidine derivatives

The present invention covers new quinoline compounds of general formula (I) in which A, R, R, R, R, R, R, and Q are as defined herein, methods of preparing said compounds, intermediate compounds useful for preparing said compounds, pharmaceutical compositions and combinations comprising said compounds and the use of said compounds for manufacturing pharmaceutical compositions for the treatment, control and/or prevention of diseases, in particular of helminth infections, as a sole agent or in combination with other active ingredients. 

Anthelmintic quinoline-3-carboxamide derivatives

The present invention covers Pyrazolopyrimidine compounds of general formula (I), in which n, o, X, Y, R, Q, R, R, Rand Rare as defined herein, methods of preparing said compounds, intermediate compounds useful for preparing said compounds, pharmaceutical compositions and combinations comprising said compounds and the use of said compounds for manufacturing pharmaceutical compositions for the treatment, control and/or prevention of diseases, in particular of helminth infections, as a sole agent or in combination with other active ingredients. 

Growing community of inventors

Dormagen, Germany

Nils Griebenow